Compare CVS Health Corp (CVS) vs Williams Companies Inc (WMB) Price & Performance

CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.

The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.

WMB trades at $70.4, down 1.9% on the day, amid a bearish technical signal. The company reported mixed Q2 2026 earnings, missing EPS estimates but raising full-year EBITDA guidance to $8.4 billion. Strong profitability is evident with a 25.18% net income margin and 24.02% ROE, though valuation ratios like P/E of 28.05 appear elevated. The recent $5.5 billion acquisition of Momentum Midstream aims to bolster growth in the Haynesville region.

Outlook remains positive with analyst consensus strongly bullish (79% buy ratings) and a $87.14 price target, implying significant upside. Risks include execution of the Momentum integration, volatile energy prices, and high debt levels. Cash flow stability from fee-based contracts supports the dividend, but net cash flow turned negative in 2026 forecasts.